Sengenics core Immunome protein array technology was originally developed and commercialised as a spin-off company from Cambridge University in the UK. The main focus of the company is to leverage Immunome for discovering antibody-based therapeutics and diagnostic signatures for immune system disorders.
The Immunome platform was invented by Professor Jonathan Blackburn through a collaboration between the University of Oxford and the University of Cambridge. He is the current CSO of Sengenics and the driver of the company’s R&D strategy. Sengenics owns the set of patents for both the fundamental underlying technology as well as commercialisation and joint IP rights for discoveries and applications made with the Immunome platform.
In addition to the Immunome technology, Sengenics also has a clinical genomics business unit which is focused on prenatal and postnatal diagnosis and treatment using cutting-edge genomics and proteomics technologies. These products are patented and proprietary tests for Human diseases that use the GalaxC, Exomax, ThalaSURE and Genoverse brand names.
The company has been awarded a variety of international awards and has been featured in numerous commercial reports on clinical genomics and array-based proteomics. Notable awards include the 2013 Biomedical Excellence Award and the prestigious Frost and Sullivan 2014 Award for Genomics Diagnostics.